We Have Recently Made Changes to Our Website, If you are unable to find something Specific, Please Search Below

Web onlypunjab.com

Research and Markets: Nociceptive Pain - Safety Profile
Publish Date : 12/5/2004 9:50:00 AM   Source : Science and Technology News Onlypunjab.com

The nociceptive pain pipeline contains few novel drugs, instead being filled with reformulations and drug combinations. To make a drug stand out in this replete market, particularly at a time when there is great public concern about drug withdrawals, it must have an unquestionable safety profile, proven over long-term trials.

Scope

- Epidemiology of nociceptive pain across the seven major markets, as well as analysis of the main unmet needs in the current treatment of the disease
- Overview of drugs in Phase III, II, I and preclinical development, plus analysis of key companies involved in the R&D pipeline: GSK, Merck and Endo
- Comprehensive analysis of key late-stage products including DepoDur, Ionsys, Prexige, Prialt & THC monotherapy, with drug revenues forecast to 2014
- Insight into innovative early stage products, including vanilloid and Bradykinin receptors, plus analysis of key research into gene therapy for pain

Highlights

- Although pain is not a new phenomenon, better education for patients, physicians, nurses and pharmacists is still an unmet need. The current range of therapies should be sufficient for pain relief if used knowledgably.
- New COX-2 inhibiting drugs will have to provide impeccable safety data from long-term trials before gaining approval in the current climate where the whole class of drugs is suspect. If safety can be proved, the market is relatively small, and new entrants may do well.
- While experts believe morphine is still the most effective painkiller available, it can be improved upon in terms of convenience and side effects. Many opioids in development are reformulations of old drugs sustained release, or patch delivery or receptor-specific drugs aiming to reduce side effects.

Reasons to Purchase

- Enhance your sales forecasting ability and future product positioning through identification of market drivers and key competitors
- Optimise your knowledge of company strategies in the nociceptive pain market
- Identify areas of the market that are not being targeted by competitors

TABLE OF CONTENTS

CHAPTER 1 EXECUTIVE SUMMARY 3
CHAPTER 2 PATIENT POTENTIAL 31
CHAPTER 3 R&D APPROACH 56
CHAPTER 4 NOCICEPTIVE PAIN PIPELINE ANALYSIS 75
CHAPTER 5 OPIOID DRUGS LATE-STAGE DRUG ANALYSIS & FORECASTS 110
CHAPTER 6 NSAIDS LATE-STAGE DRUG ANALYSIS AND FORECASTS 163
CHAPTER 7 OTHER ANALGESICS LATE-STAGE DRUG ANALYSIS AND FORECASTS 192
CHAPTER 8 INNOVATIVE EARLY-STAGE PROJECTS 230
APPENDIX A
APPENDIX B
For more information visit http://www.researchandmarkets.com/reports/c10176

Laura Wood
Senior Manager
Research and Markets
e-mail protected from spam bots
Fax: +353 1 4100 980